Author

Joana Torres

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment

Joana Torres  et al.

Planning the patient’s journey to success in Crohn’s disease (Janssen)
Planning the patient’s journey to success in Crohn’s disease (Janssen)

Joana Torres  et al.

Walk this way: navigating the evolving UC treatment pathway (Galapagos)
Walk this way: navigating the evolving UC treatment pathway (Galapagos)

Joana Torres  et al.

IBD: Strategies for prevention
IBD: Strategies for prevention

Joana Torres

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)
JAK of all trades, master of IBD? Refocusing our clinical expectations (AbbVie)

Joana Torres  et al.

Anti-TNF's: Still the best option in Crohn's disease
Anti-TNF's: Still the best option in Crohn's disease

Joana Torres

In practice: Managing a case after failure of one biological
In practice: Managing a case after failure of one biological

Joana Torres

What do UC on the horizon: exploring the emerging management options (Janssen)
What do UC on the horizon: exploring the emerging management options (Janssen)

Joana Torres  et al.

Exploring the pre-diagnostic stages of IBD: A way forward for cure and prevention?
Exploring the pre-diagnostic stages of IBD: A way forward for cure and prevention?

Joana Torres

TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA
TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Joana Torres  et al.

CIRCULATING MIR-21 AND PREVALENCE OF IBD IN PSC PATIENTS
CIRCULATING MIR-21 AND PREVALENCE OF IBD IN PSC PATIENTS

Joana Torres  et al.

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME
PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

Joana Torres  et al.

IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI
IMPACT OF PRIOR TUMOUR NECROSIS FACTOR INHIBITOR FAILURE AND PRIOR CORTICOSTEROID USE ON THE MAINTENANCE OF EFFICACY OF TOFACITINIB FOLLOWING DOSE REDUCTION IN PATIENTS WITH ULCERATIVE COLITIS WHO WERE IN STABLE REMISSION: 6-MONTH DATA FROM THE DOUBLE-BLI

Joana Torres  et al.

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Joana Torres  et al.

SEVERE COLITIS FOLLOWING RITUXIMAB THERAPY: A RARE ENTITY
SEVERE COLITIS FOLLOWING RITUXIMAB THERAPY: A RARE ENTITY

Joana Torres  et al.

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM
NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOM

Joana Torres  et al.

IBD PATIENTS SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE PORTUGUESE COHORT OF THE IBD PODCAST STUDY
IBD PATIENTS SHOW SIGNS OF RELEVANT DISEASE ACTIVITY – RESULTS FROM THE PORTUGUESE COHORT OF THE IBD PODCAST STUDY

Joana Torres  et al.

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

Joana Torres  et al.

Item 1 - 20 / 30
1
2